Foghorn Therapeutics Inc. (NASDAQ: FHTX) reported Q3 EPS of ($0.31), $0.12 better than the analyst estimate of ($0.43). Revenue for the quarter came in at $7.81 million versus the consensus estimate of $6.34 million.

For earnings history and earnings-related data on Foghorn Therapeutics Inc. (FHTX) click here.